Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2021-D-0789

Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability

Documents

Comments

259

Description

OPEN

Key Dates

Comment Period OpensApr 14, 2022

Comment Period ClosesSep 27, 2024

Documents

Type	Title	Posted	Comments	Status
Notice	Diversity Action Plans To Improve Enrollment of Participants From Underrepresented Populations in Clinical Studies; Draft Guidance for Industry; Availability FR Doc: 2024-14284	Jun 28, 2024

Comment Statistics

Total Comments

259

Keywords

OPEN

CDER

; Draft Guidance for Industry; Availability

Racial and Ethnic Subgroups in Clinical Trials

of Participants from Underrepresented

Diversity Plans to Improve Enrollment

Data from Regulations.gov